Clinique de l'Union, Saint-Jean, Toulouse, France.
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):387-400. doi: 10.1177/039463201102400212.
To describe the sensitization profile of respiratory allergies in France, identifying factors influencing the prescription of allergen immunotherapy (AIT) [Transversal phase (T)], and assess treatment efficacy, tolerability, compliance and satisfaction [Longitudinal phase (L)]. French allergists (600) and pneumo-allergists (600) were offered participation and asked to recruit the first 20 new patients with allergic rhinitis (AR) and/or asthma, consulting for a first time allergy check-up with skin prick-test (T), and 5 patients sensitized to pollens (skin test and/or specific IgE) for whom SLIT with pollens was prescribed (L). In the T phase, 2,714 patients were recruited by 169 specialists, mostly allergists (76.5%). The majority (98%) suffered from AR, alone (57.7%) or with asthma (40.3%) and 80.3% suffered from moderate-to-severe rhinitis, mostly persistent (65.8%). Asthma, when present, was mostly intermittent (63.7%) or mild persistent (20.1%). Sensitization to house dust mites was the most common (64.5%), followed by grass pollens (61.5%), tree pollens (41.6%) and cat danders (30.5%). Poly-sensitization was seen in 73.6% of patients. AIT, mostly sublingual, was recommended in 55.6% of the patients, mostly (78.1%) because of insufficient control with symptomatic treatments. The overall impact of symptoms on QOL, positive skin test to grass pollens, ocular pruritus and/or nasal obstruction and moderate-to-severe rhinitis were significant predictors of SLIT prescription. Poly-sensitization or concomitant asthma were not seen as deterrents. Most patients consulting a specialist for allergy testing suffer from moderate-to-severe rhinitis. Treatment in current practice includes immunotherapy in half of the patients, and follows ARIA recommendations.
为了描述法国呼吸道过敏的致敏情况,确定影响变应原免疫治疗(AIT)处方的因素[横断面阶段(T)],并评估治疗的疗效、耐受性、依从性和满意度[纵向阶段(L)]。向法国过敏专家(600 名)和呼吸过敏专家(600 名)提供了参与机会,并要求他们招募 20 名首次因过敏检查进行皮肤点刺试验(T)就诊的新过敏性鼻炎(AR)和/或哮喘患者,以及 5 名对花粉过敏(皮肤试验和/或特异性 IgE)且开处花粉舌下免疫治疗(L)的患者。在 T 阶段,169 名专家共招募了 2714 名患者,其中大多数为过敏专家(76.5%)。大多数患者(98%)患有 AR,单独(57.7%)或合并哮喘(40.3%),80.3%患有中重度鼻炎,大多数为持续性(65.8%)。存在哮喘时,多为间歇性(63.7%)或轻度持续性(20.1%)。尘螨致敏最为常见(64.5%),其次为草花粉(61.5%)、树花粉(41.6%)和猫皮屑(30.5%)。73.6%的患者存在多敏化。建议对 55.6%的患者进行 AIT,主要为舌下免疫治疗,主要原因是症状治疗的控制不足(78.1%)。症状对 QOL 的总体影响、对草花粉的阳性皮肤试验、眼痒和/或鼻阻塞以及中重度鼻炎,是决定是否进行 SLIT 处方的重要预测因素。多敏化或同时合并哮喘并不被视为阻碍因素。大多数因过敏测试就诊的患者均患有中重度鼻炎。当前实践中的治疗方法包括对一半患者进行免疫治疗,并遵循 ARIA 建议。